Lakewood-Amedex Biotherapeutics Inc. — Form S-1
Filed September 18, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 78/100
What the filing says
Lakewood-Amedex (Nevada corp, ~$5M assets) filed Form S-1 to register resale of 4,512,400 common shares issuable upon conversion of Series C Convertible Preferred Stock by a single selling stockholder. The shares have $0.0001 par value. Counsel (Lucosky Brookman) opines shares will be duly authorized, validly issued, fully paid, and non-assessable upon conversion per the Certificate of Designation. Filing dated September 18, 2026; financial statements restated as of March 11, 2026, and include a one-for-ten reverse stock split (August 21, 2026) and prior one-for-5.92 reverse stock split (January 9, 2026).
Why this rating
4.5M shares from preferred conversion is material relative to $5M asset base and likely represents significant dilution; however, this is a routine S-1 for resale registration with standard legal opinions. Multiple reverse splits suggest capital stress but are already executed.
Price action (we called it neutral)
before filing · preread $1.93 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.